Timothy Hermes

Vice President of Market Access

Timothy Hermes joined HepQuant as Vice President of Market Access in September 2021 with more than 30 years experience in the pharmaceutical industry. In this role, Mr. Hermes leads HepQuant’s market access strategy, including government relations and exploration of payer and reimbursement opportunities.

Mr. Hermes has worked on a variety of complex coverage and reimbursement issues in the past, most notably changing a Medicare Least Costly Alternative coverage policy that was keeping seniors with Chronic Obstructive Pulmonary Disease from accessing an important new drug. 

More recently, Mr. Hermes served as Vice President of Market Access at Aurinia Pharmaceuticals where he created and implemented the market access launch plan for voclosporin, the first FDA-approved oral therapy for lupus nephritis (LN). In this role he was responsible for conducting the pricing studies, building the economic models, and devising the overall strategy to optimize payer coverage. LN is a condition that causes irreversible kidney damage and increases the risk of kidney failure. 

Prior to Aurinia, Mr. Hermes served in a similar leadership position for Ablynx, now Sanofi-Genzyme, where he built and implemented a payer reimbursement and coverage strategy that maximized both across the payer and hospital inpatient landscapes for caplacizumab, a biologic indicated for acquired thrombotic thrombocytopenic purpura, a potentially fatal blood disease. In addition to similar past positions in government affairs and market access within the pharmaceutical industry, Mr. Hermes also spent three years as a market access consultant to the pharma industry specializing in Medicare coding, coverage, and payment for a variety of products, including drug-device combination products.  He holds a Bachelor of Sciences degree from Centenary College in Shreveport, LA.